Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers.

Genome medicine - 26 Apr 2023

Hutchinson Katherine E, Chen Jessica W, Savage Heidi M, Stout Thomas J, Schimmoller Frauke, Cortés Javier, Dent Susan, Harbeck Nadia, Jacot William, Krop Ian, Trabucco Sally E, Sivakumar Smruthy, Sokol Ethan S, Wilson Timothy R

Abstract excerpt

BACKGROUND: Mutations in the p110α catalytic subunit of phosphatidylinositol 3-kinase (PI3K), encoded by the PIK3CA gene, cause dysregulation of the PI3K pathway in 35-40% of patients with HR+/HER2- breast cancer. Preclinically, cancer cells harboring double or multiple PIK3CA mutations (mut) elicit hyperactivation of the PI3K pathway leading to enhanced sensitivity to p110α inhibitors. METHODS: To understand the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Fulvestrant

Share to Mutation

Share to Phosphatidylinositol 3-Kinases

Share to PI3K/AKT/mTOR signaling in cancer

Share to Receptor, ErbB-2

Source

Open in PubMed Open full text

Identifiers

PMID: 37101291
DOI: 10.1186/s13073-023-01181-8
PMCID: PMC10131374

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers.PMID 37101291Read ↗

Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations.Semantic proximity Read ↗

Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors.Semantic proximity Read ↗

Comparative genomic analysis of PIK3R1-mutated and wild-type breast cancers.Semantic proximity Read ↗

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.Semantic proximity Read ↗

Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.Semantic proximity Read ↗

Genomic determinants of response to alpelisib plus fulvestrant in the SOLAR-1 trial.Semantic proximity Read ↗

Frequency and spectrum of PIK3CA somatic mutations in breast cancer.Semantic proximity Read ↗

PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy.Semantic proximity Read ↗

Dynamic Monitoring and Identification of Reliable Biomarkers to Predict Efficacy of Bireociclib and Fulvestrant: An Exploratory ctDNA Analysis of the BRIGHT-2 StudySemantic proximity Read ↗

Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations.Semantic proximity Read ↗

Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted TherapeuticsSemantic proximity Read ↗

PIK3CA Mutations are Common in Many Tumor Types and are Often Associated With Other Driver Mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.